Tricard (trimetazidine) coated tablets 20 mg. №30

Description

Tricard (trimetazidine) coated tablets 20 mg. №30

Composition

active substance: 1 tablet contains trimetazidine dihydrochloride 20 mg;

Excipients: corn starch, mannitol (E 421), povidone, magnesium stearate, talc;

shell: Opadry II Red film coating compound (polyethylene glycol, polyvinyl alcohol, titanium dioxide (E 171), yellow FCF (E 110), ponso 4R (E 124), talc).

Dosage form

Film-coated tablets.

Main physical and chemical properties: round tablets with a biconvex surface, covered with a red film coating.

Pharmacotherapeutic group

Cardiac drugs. Trimetazidine.
ATX code C01E B15.

Pharmacological properties

It is an anti-ischemic and antianginal agent. Prevents a decrease in the level of ATP in the cell, ensuring the proper operation of ion pumps, transmembrane sodium-potassium flow. Helps increase glucose oxidation by optimizing energy processes in cells.

Indications

Tricard is prescribed to adults for the symptomatic treatment of stable angina (with insufficient efficacy / intolerance of first-line antianginal drugs).

Contraindications

Tricard cannot be prescribed:

• in case of trimetazidine allergy;
• in case of intolerance of components;
• in Parkinson’s disease;
• with symptoms of parkinsonism (tremor, muscle rigidity);
• with “restless legs” syndrome or other related motor disorders;
• in chronic kidney disease in stage IV-V.

It is necessary to prescribe this drug with caution:

• patients with chronic kidney disease in stage I-III (it is recommended to monitor functional parameters with dose adjustment);
• elderly patients (over 75 years).

Use during pregnancy and breastfeeding

Due to the lack of clinical data, this drug is not recommended for use in pregnant / lactating women.

Method of application and dose

Tricard tablets are intended for oral administration (orally) with food, washed down with sufficient clean water.
Recommended dosage: 1 tablet (20 mg) x3 times / day. The duration of the therapeutic course is set individually and depends on the course and severity of the disease.
The recommended dosage for patients with chronic kidney disease in stage I-III – 1 tablet (20 mg) x2 times / day – morning and evening.

Overdose

The wide therapeutic range of the drug makes the possibility of serious intoxication unlikely.
In case of overdose (significant overdose) there may be a decrease in peripheral vascular resistance, and as a consequence, the development of hypotension, flushing. In such cases, symptomatic therapy is recommended.

Side effects:

• On the part of the nervous system: headache, extrapyramidal symptoms (gait instability, tremor, akinesia, muscle hypertonia, restless legs syndrome, other movement disorders), dizziness, sleep disorders (drowsiness, insomnia).
• Co digestive side: pain in the epigastric (above the stomach) area of ​​the abdomen, nausea / vomiting, diarrhea, constipation.
• General disorders: asthenia.
• Cardiovascular side: arterial hypotension, incl. orthostatic hypotension (may be associated with dizziness, malaise, falls), flushing, extrasystole, palpitations, tachycardia.
• Co side of the skin, subcutaneous tissues: rash, erythema, generalized exanthematous pustular rash, itching, urticaria, angioneurotic edema.
• Co side of the hepatobiliary system: hepatitis.
• Co side of the blood system, lymphatic system: agranulocytosis, thrombocytopenic purpura, thrombocytopenia.
• Due to the presence of dyes in the tablets (E110, E124) may develop allergic reactions, asthma, especially in patients with allergies to acetylsalicylic acid.